CLGN - CollPlant Biotechnologies Ltd.

NasdaqGM - NasdaqGM Real-time price. Currency in USD

CollPlant Biotechnologies Ltd.

Weizmann Science Park
4 Oppenheimer
Rehovot 7670104
972 73 232 5600

Full-time employees73

Key executives

NameTitlePayExercisedYear born
Mr. Yehiel TalCEO & Director865kN/A1952
Mr. Eran Rotem CPADeputy CEO & CFO651kN/A1968
Ms. Michal RoytmanVP of Sales & Marketing228kN/A1985
Prof. Oded ShoseyovFounder & Non-Exec. Chief ScientistN/AN/A1956
Mr. Oren FahimipoorVP of OperationsN/AN/A1982
Ms. Hadas Dreiher HorowitzVP of HRN/AN/A1977
Dr. Elana GazalVP, R&DN/AN/A1975
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

Corporate governance

CollPlant Biotechnologies Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.